Infertility Urological and Genital Diseases
Conditions
Interventions
A prospective study was conducted between February 2022 and February 2023 on 45 subfertile patients who had undergone an infertility study in which the NaProTechnology and the RRM approaches were cons
Sponsors
Clinical Consulting G&E
Eligibility
Sex/Gender
Female
Age
35 Years to 42 Years
Inclusion criteria
Inclusion criteria: 1. Women who wished to be treated using NaPro-Technology and an RRM approach 2. Functional gynecological pathologies that could affect follicular development were considered for treatment, such as hypothyroidism, hirsutism, hyperandrogenemia, luteal-phase defects, delayed maturation of follicular development, polycystic ovary syndrome (PCOS) and other causes such as stress, hyperprolactinemia, or pre-obesity
Exclusion criteria
Exclusion criteria: 1. Patients who required surgery to resolve an infertility problem 2. Any pathology that required more time to resolve, such as premature ovarian failure, azoospermia, hyperprolactinemia secondary to pituitary microadenomas 3. Patients with hyperthyroidism, obesity, or anorexia 4. Pathologies requiring further intervention, either surgical or prolonged medical intervention 5. Myomatous uterus requiring surgical intervention or hyperplasia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hexagonal crystallization pattern type P, measured using endocervical liquid biopsies collected within the fertile window from 3 days before the Peak Day (P Day) until P Day, which is the last day with fertile mucus according to CrMS | — |
Secondary
| Measure | Time frame |
|---|---|
| The final pregnancy outcome is determined by recording a positive urine HCG pregnancy in the patient's medical history, or by confirmation by the patient that she has become pregnant | — |
Countries
Spain
Contacts
Public ContactJosé María Murcia Lora
Outcome results
None listed